Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. Thank you for attending today's Arcus Biosciences second quarter 2024 earnings call. My name is Tamia and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the conference over to your host, Pia Ease, Vice President of Investor Relations and Strategy. You may proceed. Hello everyone and thank you for joining us on today's conference call to discuss ARCIS' second quarter 2024 financial results and pipeline updates. I'd like to remind you that on this call, management will make forward-looking statements, including statements about our cash runway and our expected clinical development milestones and timelines. All statements, other than historical facts, reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our most recent annual report on Form 10-K and quarterly report on Form 10-Q that have been filed with the SEC. We strongly encourage you to review our filings. Today, you'll hear from our CEO, Terry Rosen, COO, Jennifer Jarrett, and CFO, Bob Gels. We'll also be joined by our CMO, Dimitri Naughton, and President, Juan Jaen, for questions after the prepared remarks. With that, I'll turn the call over to Terry. Thanks very much, Pia, and thank you all for joining us this afternoon. 2024 has already been a very exciting year for us and also very consequential. We completed an enrollment of our first Phase III trial, STAR-221, 1,000-plus patient study in first-line upper GI adeno...